FDA approves first new sunscreen ingredient in over 25 years
The US Food and Drug Administration on June 9 cleared bemotrizinol, a new sunscreen active ingredient, for the American market. As reported by STAT News, it is the first new sunscreen active ingredient approved in the United States since 1999, although the molecule has been sold in Europe for decades under names such as Tinosorb S and Parsol Shield.
Bemotrizinol is a chemical filter that absorbs photon energy across both the UVA and UVB bands, delivering broad-spectrum protection. It is photostable on the skin surface and helps preserve the structure of other active ingredients in the same formulation, improving both safety and usability.
American and European regulatory regimes have long operated very differently. The European Union assesses sunscreen ingredients in the cosmetic category, while the FDA treats them as over-the-counter drugs, demanding far more comprehensive clinical dossiers for new molecules. STAT News reports that this divergence is the main reason bemotrizinol waited 25 years for US approval despite its long European track record.
The FDA used the framework established by the 2020 CARES Act for sunscreen regulation rather than the pre-2014 monograph process. That act modernized the older monograph and created a more predictable approval pathway for over-the-counter products.
On the industry side, the decision opens a new design space for American formulators. Most existing US sunscreens have worked from a constrained palette of actives in terms of photostability and skin feel. Combining bemotrizinol with existing ingredients such as zinc oxide or avobenzone allows lighter-feeling formulations with no white cast.
Dermatologists stress that broad-spectrum UVA protection is especially important. UVA radiation penetrates the deeper dermis and is a major driver of photoaging and melanoma risk. STAT cites the American Academy of Dermatology welcoming the addition as a way to strengthen the protective palette.
The fact that the FDA had not approved a new active since 1999 has long been criticized by public-health experts and clinicians. In expert commentary cited by STAT, Yale University dermatologist Dr David Leffell said the decision is 'critical to catching up with modern sun-protection standards.'
It is not yet clear when manufacturers will bring new formulations to shelves. STAT reports that major chemical suppliers such as BASF and DSM-Firmenich plan to start supplying US customers within six to 12 months. Existing American brands are expected to refresh their formulations in parallel.
Other ingredients still in regulatory limbo include bisoctrizole, drometrizole trisiloxane and diethylamino hydroxybenzoyl hexyl benzoate — all approved in Europe and still awaiting FDA assessment. The bemotrizinol decision could accelerate those reviews as well.
Sunburn and skin cancer cost the American public health system billions of dollars each year. CDC figures indicate that the majority of skin-cancer cases are linked to sun-driven UV exposure. This is not medical advice; consult your dermatologist about skin health and product choices.
Read next
World's largest opioid review finds they often do not work
The largest review yet of opioid use in chronic pain has concluded that the drugs often deliver disappointing results across many clinical situations, Science Daily reports. The researchers say prescribing practices should be revisited.
Doctors and the NHS could be sued for mistakes made by AI tools, report warns
According to the Guardian, a new Medical Protection Society report finds that doctors and NHS services could be sued over mistakes made by AI tools used in clinical practice. The report calls for an urgent update to insurance and liability frameworks.
Tea benefits your health and longevity — how you drink it matters
A new international study reported by Science Daily finds regular tea drinking may reduce cardiovascular risk and all-cause mortality. The researchers stress, however, that the effect depends on daily dose, preparation style and whether you add milk or sugar.
Weight-loss drugs drive global whey protein supply toward shortage
Global demand for whey protein is hitting record levels as millions of patients on GLP-1 weight-loss drugs turn to high-protein diets to offset muscle loss, the Guardian reports. Suppliers say production capacity is already pushed close to its limits.
Advanced prostate cancer radiotherapy to cut sessions from 20 to five
England's NHS has approved a high-precision radiotherapy schedule for prostate cancer that compresses treatment from 20 sessions over four weeks to five sessions in a week and a half. The BBC reports the change will affect about 10,000 men a year and cut hospital trips by two-thirds.
